Skip to main content
SpringerLink
Log in

Lowering Low-Density Lipoprotein Cholesterol Levels to Reduce Atherosclerotic Coronary Heart Disease Risk

  • Chapter
Therapeutic Lipidology

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 777 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bays HE, McGovern ME. Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. Prev Cardiol 2005;8(4):226–33.

    Article  PubMed  CAS  Google Scholar 

  2. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia–current therapies and future agents. Expert Opin Pharmacother 2003 November;4(11):1901–38.

    Article  Google Scholar 

  3. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003 May;4(5):779–90.

    PubMed  Google Scholar 

  4. Bays HE. Combination lipid-altering drug therapy with statins - an update. www.lipidsonline.org, Accessed April 2005.

    Google Scholar 

  5. Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther 2005 September;3(5):789–820.

    Article  Google Scholar 

  6. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004; 2(4):485–501.

    Article  PubMed  CAS  Google Scholar 

  7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 November 19;344(8934):1383–89.

    Google Scholar 

  8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May 27;279(20):1615–22.

    Article  PubMed  CAS  Google Scholar 

  9. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 April 5;361(9364):1149–58.

    Article  PubMed  CAS  Google Scholar 

  10. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998 December 8;98(23):2513–9.

    PubMed  CAS  Google Scholar 

  11. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 July 6;360(9326):7–22.

    Google Scholar 

  12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998 November 5;339(19):1349–57.

    Google Scholar 

  13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 November 16;333(20):1301–7.

    Article  PubMed  CAS  Google Scholar 

  14. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 April 7;352(14):1425–35.

    Article  PubMed  CAS  Google Scholar 

  15. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 November 23;360(9346):1623–30.

    Article  PubMed  CAS  Google Scholar 

  16. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol 2005; 1(1):39–59.

    Article  CAS  Google Scholar 

  17. Bays HE. Collaborative Atorvastatin Diabetes Study (CARDS). Lipids Online Commentaries on Research. http://www.lipidsonline.org, Accessed 24 July 2005.

    Google Scholar 

  18. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 August 21;364(9435):685–96.

    Article  PubMed  CAS  Google Scholar 

  19. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001 May 1;87(9):1074–79.

    Article  PubMed  CAS  Google Scholar 

  20. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 June 14;361(9374):2005–16.

    Article  PubMed  CAS  Google Scholar 

  21. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 April 5;361(9364):1149–58.

    Article  PubMed  CAS  Google Scholar 

  22. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 November 23;360(9346):1623–30.

    Article  PubMed  CAS  Google Scholar 

  23. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992 July;15(7):820–5.

    Article  CAS  Google Scholar 

  24. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997 April;20(4):614–20.

    Article  CAS  Google Scholar 

  25. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999 December 13;159(22):2661–7.

    Article  PubMed  CAS  Google Scholar 

  26. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998 December 8;98(23):2513–9.

    PubMed  CAS  Google Scholar 

  27. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003 October;26(10):2713–21.

    Article  PubMed  CAS  Google Scholar 

  28. Serruys PW, de FP, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 June 26;287(24):3215–22.

    Article  PubMed  CAS  Google Scholar 

  29. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005 July 21;353(3):238–48.

    Article  PubMed  CAS  Google Scholar 

  30. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002 December 9;162(22):2597–604.

    Article  CAS  Google Scholar 

  31. DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001 March 24;357(9260):905–10.

    Article  Google Scholar 

  32. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 December 17;106(25):3143–421.

    Google Scholar 

  33. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 July 13;110(2):227–39.

    Article  PubMed  Google Scholar 

  34. Brunner E, Thorogood M, Rees K, et al. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2005 October 19;4:CD002128.

    Google Scholar 

  35. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998 March 1;81(5):582–7.

    Article  PubMed  CAS  Google Scholar 

  36. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003 July 15;92(2):152–60.

    Article  PubMed  CAS  Google Scholar 

  37. van HM, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000 April;129(8):1748–54.

    Article  Google Scholar 

  38. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001 August;23(8):1209–30.

    Article  PubMed  CAS  Google Scholar 

  39. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004 November;26(11):1758–73.

    Article  PubMed  CAS  Google Scholar 

  40. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003 March 15;91(6):667–72.

    Article  PubMed  CAS  Google Scholar 

  41. Bays HE. Commentary: Trial finds that simvastatin plus niacin is safe in people with coronary artery disease and low HDL cholesterol. Evid Based Cardiovasc Med 2004;8:173–6.

    Article  Google Scholar 

  42. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002 November;11(11):1587–604.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Harold E. Bays MD,FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Director of Preventive Cardiology, Rush University Medical Center Radiant Research, Chicago, IL

    Michael H. Davidson MD,FACC,FACP

  2. Director of Preventive Cardiology, Sterling Rock Falls Clinic Chief of Medicine CGH Medical Center Clinical Associate Professor, University of Illinois College of Medicine, Peoria, IL

    Peter P. Toth MD,PhD,FAAP,FICA,FAHA,FCCP,FACC

  3. Southern Illinois University School of Medicine, Springfield, IL

    Peter P. Toth MD,PhD,FAAP,FICA,FAHA,FCCP,FACC

  4. Chief Science Officer,Provident Clinical Research, Bloomington, IN

    Kevin C. Maki PhD

  5. Weill Cornell Medical College, New York, NY

    Antonio M. Gotto Jr MD,DPhil

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Bays, H.E. (2007). Lowering Low-Density Lipoprotein Cholesterol Levels to Reduce Atherosclerotic Coronary Heart Disease Risk. In: Davidson, M.H., Toth, P.P., Maki, K.C., Gotto, A.M. (eds) Therapeutic Lipidology. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-533-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-533-6_11

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-551-4

  • Online ISBN: 978-1-59745-533-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation